Multiple myeloma (MM) is seldom curable and a majority of patients experience a relapse after initial responses. This has led to a particularly high demand for alternative treatments, such as those that target the CD38 surface antigen. MOR202 induces antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) mediated killing of multiple myeloma cells.
MOR202 is a fully human monoclonal antibody (mAb) directed against CD38, which is one of the most strongly and uniformly expressed antigens on the surface of malignant plasma cells, and is an established diagnostic marker for multiple myeloma. Antibody-dependent cell-mediated cytotoxicity (ADCC) is the primary mode of action of MOR202.
MOR 202 is currently under clinical investigation in a Phase 1 / 2a trial * in patients with relapsed / refractory multiple myeloma (MM).In an, open-label, multi-center, dose-escalation study MOR202 will be evaluated at escalating doses alone and in combination with lenalidomie and pomalidomide.
The antibody already showed encouraging interim data on safety and tolerability in patients with relapsed/refractory multiple myeloma. MOR202 is well tolerated and can be safely administered as an intravenous infusion with best in class profile.